June 17, 2020 / 1:29 PM / 15 days ago

BRIEF-BioMarin Provides New Data from Study Of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

June 17 (Reuters) - Biomarin Pharmaceutical Inc:

* BIOMARIN PROVIDES ADDITIONAL DATA FROM RECENT 4 YEAR UPDATE OF ONGOING PHASE 1/2 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A IN LATE-BREAKING ORAL PRESENTATION AT WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below